Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 2 minute read Pharma Industry News Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for… bypharmanewsdailyJune 18, 2020
